287 related articles for article (PubMed ID: 32950258)
1. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia.
Ulhaq ZS; Soraya GV
Med Clin (Barc); 2020 Dec; 155(12):548-556. PubMed ID: 32950258
[No Abstract] [Full Text] [Related]
2. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Zhang Y; Zhong Y; Pan L; Dong J
Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
Montesarchio V; Parrela R; Iommelli C; Bianco A; Manzillo E; Fraganza F; Palumbo C; Rea G; Murino P; De Rosa R; Atripaldi L; D'Abbraccio M; Curvietto M; Mallardo D; Celentano E; Grimaldi AM; Palla M; Trojaniello C; Vitale MG; Million-Weaver SL; Ascierto PA
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32784217
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
Fernández-Ruiz M; López-Medrano F; Pérez-Jacoiste Asín MA; Maestro de la Calle G; Bueno H; Caro-Teller JM; Catalán M; de la Calle C; García-García R; Gómez C; Laguna-Goya R; Lizasoáin M; Martínez-López J; Origüen J; Pablos JL; Ripoll M; San Juan R; Trujillo H; Lumbreras C; Aguado JM
J Med Virol; 2021 Feb; 93(2):831-842. PubMed ID: 32672860
[TBL] [Abstract][Full Text] [Related]
5. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.
Comel AC; Mosaner W; Bragantini D; Lanzafame M
Infection; 2021 Feb; 49(1):195-196. PubMed ID: 32557206
[No Abstract] [Full Text] [Related]
6. Is IL-6 a key cytokine target for therapy in COVID-19?
Jones SA; Hunter CA
Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
[TBL] [Abstract][Full Text] [Related]
7. Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Mar; 384(9):e46. PubMed ID: 33657301
[No Abstract] [Full Text] [Related]
8. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
9. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.
Samaee H; Mohsenzadegan M; Ala S; Maroufi SS; Moradimajd P
Int Immunopharmacol; 2020 Dec; 89(Pt A):107018. PubMed ID: 33045577
[TBL] [Abstract][Full Text] [Related]
11. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
[TBL] [Abstract][Full Text] [Related]
12. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date.
Kenny G; Mallon PWG
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1279-1287. PubMed ID: 34187281
[No Abstract] [Full Text] [Related]
14. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
Smetana K; Brábek J
In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
[TBL] [Abstract][Full Text] [Related]
15. Observational study on off-label use of tocilizumab in patients with severe COVID-19.
Albertini L; Soletchnik M; Razurel A; Cohen J; Bidegain F; Fauvelle F; Safrano G; Piquet J; Maurer C; Goldgran-Toledano D
Eur J Hosp Pharm; 2021 Jan; 28(1):22-27. PubMed ID: 32912961
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
[TBL] [Abstract][Full Text] [Related]
17. Rethinking interleukin-6 blockade for treatment of COVID-19.
Scherger S; Henao-Martínez A; Franco-Paredes C; Shapiro L
Med Hypotheses; 2020 Nov; 144():110053. PubMed ID: 32758889
[TBL] [Abstract][Full Text] [Related]
18. High Induction of IL-6 Secretion From hUCMSCs Optimize the Potential of hUCMSCs and TCZ as Therapy for COVID-19-Related ARDS.
Lo HY; Cheng SP; Huang JL; Chang KT; Chang YL; Huang CH; Chang CJ; Chiu CH; Chen-Yang YW; Chan CK
Cell Transplant; 2021; 30():9636897211054481. PubMed ID: 34757857
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?
Buryachkovskaya L; Lomakin N; Melkumyants A; Docenko J; Serebruany V
Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):e81-e82. PubMed ID: 34185077
[No Abstract] [Full Text] [Related]
20. Hemoperfusion with CytoSorb as Adjuvant Therapy in Critically Ill Patients with SARS-CoV2 Pneumonia.
Rampino T; Gregorini M; Perotti L; Ferrari F; Pattonieri EF; Grignano MA; Valente M; Garrone A; Islam T; Libetta C; Sepe V; Albertini R; Bruno R; Belliato M
Blood Purif; 2021; 50(4-5):566-571. PubMed ID: 33181508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
